OceanTech Acquisitions I Corp. (NASDAQ:OTEC) announced this morning that it has mutually terminated its combination with drug developer Captura Biopharma.
The parties did not disclose any further details on the termination of the $224 million deal, which was originally announced just two months ago in August, but it is likely that current public market conditions played a role.
In May, OceanTech extended the business combination timeline by six months from June 2 to December 2. The SPAC originally came into the deal with an estimated $106 million in trust and did not supplement this with a PIPE, although it was only required to maintain $5 million in cash available for close.
OceanTech and Captura Biopharma mark the 48th deal to be terminated this year. OceanTech, however, did note in today’s press release that it intends to seek an alternative business combination.
The SPAC initially announced the pricing of its $100 million IPO in May 2021 and intends to combine with a target valued at $250 million to $1 billion in the leisure marine, yachting or super-yachting industries.
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...
At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...
Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...
Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...